Skip to main content
Erschienen in:

16.12.2017 | Demenz | zertifizierte fortbildung

Neurodegenerative Erkrankungen

Neue Kriterien für die Diagnose der Demenz mit Lewy-Körpern

verfasst von: Adina Wagner, Eric Tönnies, Sebastian Sennock, Lisa Leikeim, Anna Gronewold, Johanna Klag, Prof. Dr. med. Richard Dodel

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die hohe Zahl Erkrankter macht die Demenzen mit Lewy-Körpern zu einem Thema von Relevanz. Für die Diagnose bleibt die klinische Symptomatik wichtigster Anhaltspunkt und noch immer kann die Erkrankung nur symptomatisch behandelt werden. Neue Möglichkeiten der Bildgebung und ein Umdenken hinsichtlich der Pathophysiologie bilden die Basis für interessante Neuentwicklungen.
Literatur
1.
Zurück zum Zitat McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2017. 89(1): p. 88–100.CrossRefPubMedPubMedCentral McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2017. 89(1): p. 88–100.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Aarsland, D., Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord, 2016. 22 Suppl 1: p. S144–8.CrossRefPubMed Aarsland, D., Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord, 2016. 22 Suppl 1: p. S144–8.CrossRefPubMed
3.
Zurück zum Zitat Howlett, D.R., et al., Regional multiple pathology scores are associated with cognitive decline in Lewy Body Dementias. Brain Pathol, 2015. 25(4): p. 401–8.CrossRefPubMed Howlett, D.R., et al., Regional multiple pathology scores are associated with cognitive decline in Lewy Body Dementias. Brain Pathol, 2015. 25(4): p. 401–8.CrossRefPubMed
4.
Zurück zum Zitat Schulz-Schaeffer, W.J., Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s Disease? Biomolecules, 2015. 5(3): p. 1467–79.CrossRefPubMedPubMedCentral Schulz-Schaeffer, W.J., Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s Disease? Biomolecules, 2015. 5(3): p. 1467–79.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Uchihara, T. and B.I. Giasson, Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol, 2016. 131(1): p. 49–73.CrossRefPubMed Uchihara, T. and B.I. Giasson, Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol, 2016. 131(1): p. 49–73.CrossRefPubMed
6.
Zurück zum Zitat Dettmer, U., D. Selkoe, and T. Bartels, New insights into cellular alpha-synuclein homeostasis in health and disease. Curr Opin Neurobiol, 2016. 36: p. 15–22.CrossRefPubMed Dettmer, U., D. Selkoe, and T. Bartels, New insights into cellular alpha-synuclein homeostasis in health and disease. Curr Opin Neurobiol, 2016. 36: p. 15–22.CrossRefPubMed
7.
Zurück zum Zitat Sumi-Akamaru, H., et al., High expression of alpha-synuclein in damaged mitochondria with PLA2G6 dysfunction. Acta Neuropathol Commun, 2016. 4: p. 27.CrossRefPubMedPubMedCentral Sumi-Akamaru, H., et al., High expression of alpha-synuclein in damaged mitochondria with PLA2G6 dysfunction. Acta Neuropathol Commun, 2016. 4: p. 27.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Barthelemy, N.R., et al., differential mass spectrometry pofiles of Tau protein in the cerebrospinal fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. J Alzheimers Dis. 2016;51(4):1033–43.CrossRefPubMed Barthelemy, N.R., et al., differential mass spectrometry pofiles of Tau protein in the cerebrospinal fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. J Alzheimers Dis. 2016;51(4):1033–43.CrossRefPubMed
9.
Zurück zum Zitat Lin, C.L., et al., Amyloid-beta suppresses AMP-activated protein kinase (AMPK) signaling and contributes to alpha-synuclein-induced cytotoxicity. Exp Neurol, 2016. 275 Pt 1: p. 84–98.CrossRefPubMed Lin, C.L., et al., Amyloid-beta suppresses AMP-activated protein kinase (AMPK) signaling and contributes to alpha-synuclein-induced cytotoxicity. Exp Neurol, 2016. 275 Pt 1: p. 84–98.CrossRefPubMed
10.
Zurück zum Zitat Pieri, L., et al., Cellular response of human neuroblastoma cells to alpha-synuclein fibrils, the main constituent of Lewy bodies. Biochim Biophys Acta, 2016. 1860(1 Pt A): p. 8–19.CrossRefPubMed Pieri, L., et al., Cellular response of human neuroblastoma cells to alpha-synuclein fibrils, the main constituent of Lewy bodies. Biochim Biophys Acta, 2016. 1860(1 Pt A): p. 8–19.CrossRefPubMed
11.
Zurück zum Zitat Calo, L., et al., Synaptic failure and alpha-synuclein. Mov Disord, 2016. 31(2): p. 169–77.CrossRefPubMed Calo, L., et al., Synaptic failure and alpha-synuclein. Mov Disord, 2016. 31(2): p. 169–77.CrossRefPubMed
12.
Zurück zum Zitat Sampson, T.R., et al., Gut microbiota regulate motor deficits and neuroinflammation in a Model of Parkinson’s Disease. Cell, 2016. 167(6): p. 1469–1480 e12.CrossRefPubMedPubMedCentral Sampson, T.R., et al., Gut microbiota regulate motor deficits and neuroinflammation in a Model of Parkinson’s Disease. Cell, 2016. 167(6): p. 1469–1480 e12.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Aldecoa, I., et al., Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neurosci Lett, 2015. 602: p. 145–9.CrossRefPubMed Aldecoa, I., et al., Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neurosci Lett, 2015. 602: p. 145–9.CrossRefPubMed
14.
Zurück zum Zitat Wahlund, L.O., et al., Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Imaging, 2017. 8(1): p. 79–90.CrossRefPubMed Wahlund, L.O., et al., Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Imaging, 2017. 8(1): p. 79–90.CrossRefPubMed
15.
Zurück zum Zitat Scheltens et al., Atrophy of medial temporal lobes on MRI in „probable“ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72.CrossRefPubMedPubMedCentral Scheltens et al., Atrophy of medial temporal lobes on MRI in „probable“ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Pasquier et al., Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268–72.CrossRefPubMed Pasquier et al., Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268–72.CrossRefPubMed
17.
Zurück zum Zitat Harper, L., et al., MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016. 139(Pt 4): p. 1211–25.CrossRefPubMedPubMedCentral Harper, L., et al., MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016. 139(Pt 4): p. 1211–25.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Papathanasiou, N.D., et al., Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord, 2012. 18(3): p. 225–9.CrossRefPubMed Papathanasiou, N.D., et al., Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord, 2012. 18(3): p. 225–9.CrossRefPubMed
19.
Zurück zum Zitat Shimizu, S., et al., Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease. Eur J Nucl Med Mol Imaging, 2016. 43(1): p. 184–92.CrossRefPubMed Shimizu, S., et al., Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease. Eur J Nucl Med Mol Imaging, 2016. 43(1): p. 184–92.CrossRefPubMed
20.
Zurück zum Zitat Brigo, F., G. Turri, and M. Tinazzi, 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci, 2015. 359(1-2): p. 161–71.CrossRefPubMed Brigo, F., G. Turri, and M. Tinazzi, 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci, 2015. 359(1-2): p. 161–71.CrossRefPubMed
21.
Zurück zum Zitat Treglia, G. and E. Cason, Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging, 2012. 22(2): p. 111–7.CrossRefPubMed Treglia, G. and E. Cason, Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging, 2012. 22(2): p. 111–7.CrossRefPubMed
22.
Zurück zum Zitat Chiba, Y., et al., Early differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT. Psychiatry Res, 2016. 249: p. 105–12.CrossRefPubMed Chiba, Y., et al., Early differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT. Psychiatry Res, 2016. 249: p. 105–12.CrossRefPubMed
24.
Zurück zum Zitat Mishima, A., et al., Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis. J Alzheimers Dis, 2016. 50(1): p. 161–74.CrossRefPubMed Mishima, A., et al., Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis. J Alzheimers Dis, 2016. 50(1): p. 161–74.CrossRefPubMed
25.
Zurück zum Zitat Bousiges, O., et al., Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-Tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer’s Disease and Dementia with Lewy Bodies. J Alzheimers Dis, 2016. 51(4): p. 1069–83.CrossRefPubMed Bousiges, O., et al., Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-Tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer’s Disease and Dementia with Lewy Bodies. J Alzheimers Dis, 2016. 51(4): p. 1069–83.CrossRefPubMed
26.
Zurück zum Zitat Wang, Z.Y., et al., Use of CSF alpha-synuclein in the differential diagnosis between Alzheimer’s disease and other neurodegenerative disorders. Int Psychogeriatr, 2015. 27(9): p. 1429–38.CrossRefPubMed Wang, Z.Y., et al., Use of CSF alpha-synuclein in the differential diagnosis between Alzheimer’s disease and other neurodegenerative disorders. Int Psychogeriatr, 2015. 27(9): p. 1429–38.CrossRefPubMed
27.
Zurück zum Zitat Petrova, M., et al., Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies. J Clin Exp Neuropsychol, 2016. 38(3): p. 354–60.CrossRefPubMed Petrova, M., et al., Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies. J Clin Exp Neuropsychol, 2016. 38(3): p. 354–60.CrossRefPubMed
28.
Zurück zum Zitat Heitz, C., et al., Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther, 2016. 8(1): p. 10.CrossRefPubMedPubMedCentral Heitz, C., et al., Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther, 2016. 8(1): p. 10.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Chwiszczuk, L., et al., Higher frequency and complexity of sleep disturbances in Dementia with Lewy Bodies as compared to Alzheimer’s Disease. Neurodegener Dis, 2016. 16(3-4): p. 152–60.CrossRefPubMed Chwiszczuk, L., et al., Higher frequency and complexity of sleep disturbances in Dementia with Lewy Bodies as compared to Alzheimer’s Disease. Neurodegener Dis, 2016. 16(3-4): p. 152–60.CrossRefPubMed
30.
Zurück zum Zitat Matsunaga, S., et al., Cholinesterase inhibitors for Lewy Body Disorders: A meta-analysis. Int J Neuropsychopharmacol, 2015. 19(2). Matsunaga, S., et al., Cholinesterase inhibitors for Lewy Body Disorders: A meta-analysis. Int J Neuropsychopharmacol, 2015. 19(2).
31.
Zurück zum Zitat Matsunaga, S., T. Kishi, and N. Iwata, Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry, 2015. 23(4): p. 373–83.CrossRefPubMed Matsunaga, S., T. Kishi, and N. Iwata, Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry, 2015. 23(4): p. 373–83.CrossRefPubMed
32.
Zurück zum Zitat Wang, H.F., et al., Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry, 2015. 86(2): p. 135–43.CrossRefPubMed Wang, H.F., et al., Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry, 2015. 86(2): p. 135–43.CrossRefPubMed
33.
Zurück zum Zitat Stinton, C., et al., Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry, 2015. 172(8): p. 731–42.CrossRefPubMed Stinton, C., et al., Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry, 2015. 172(8): p. 731–42.CrossRefPubMed
34.
Zurück zum Zitat Velayudhan L, Ffytche D, Ballard C, Aarsland D. New Therapeutic Strategies for Lewy Body Dementias. Curr Neurol Neurosci Rep. 2017;17(9):68CrossRefPubMed Velayudhan L, Ffytche D, Ballard C, Aarsland D. New Therapeutic Strategies for Lewy Body Dementias. Curr Neurol Neurosci Rep. 2017;17(9):68CrossRefPubMed
35.
Zurück zum Zitat Brand, S., et al., [Depression in Parkinson’s disease. Assessment and treatment]. Nervenarzt, 2007. 78(6): p. 715–27.CrossRefPubMed Brand, S., et al., [Depression in Parkinson’s disease. Assessment and treatment]. Nervenarzt, 2007. 78(6): p. 715–27.CrossRefPubMed
36.
37.
Zurück zum Zitat Elder, G.J., et al., Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr, 2016. 28(2): p. 341–7.CrossRefPubMed Elder, G.J., et al., Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr, 2016. 28(2): p. 341–7.CrossRefPubMed
38.
Zurück zum Zitat Groot, C., et al., The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev, 2016. 25: p. 13–23.CrossRefPubMed Groot, C., et al., The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev, 2016. 25: p. 13–23.CrossRefPubMed
39.
Zurück zum Zitat Pena, J., et al., Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology, 2014. 83(23): p. 2167–74.CrossRefPubMedPubMedCentral Pena, J., et al., Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology, 2014. 83(23): p. 2167–74.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Zhang, Q., Y.C. Kim, and N.S. Narayanan, Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci, 2015. 9: p. 293.PubMedPubMedCentral Zhang, Q., Y.C. Kim, and N.S. Narayanan, Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci, 2015. 9: p. 293.PubMedPubMedCentral
Metadaten
Titel
Neurodegenerative Erkrankungen
Neue Kriterien für die Diagnose der Demenz mit Lewy-Körpern
verfasst von
Adina Wagner
Eric Tönnies
Sebastian Sennock
Lisa Leikeim
Anna Gronewold
Johanna Klag
Prof. Dr. med. Richard Dodel
Publikationsdatum
16.12.2017
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 12/2017
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-017-2088-2

Weitere Artikel der Ausgabe 12/2017

InFo Neurologie + Psychiatrie 12/2017 Zur Ausgabe

infopharm

Nervennahrung

Neu in den Fachgebieten Neurologie und Psychiatrie

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Multiple Sklerose: Erhöhte Schubaktivität nach Impfung?

10.07.2024 EAN-Congress 2024 Kongressbericht

Ziehen Impfungen bei Multipler Sklerose (MS) in ähnlicher Weise wie Infektionen ein erhöhtes Schubrisiko nach sich? Die Effekte scheinen klein und auf einen kurzen Zeitraum begrenzt zu sein.

Akut symptomatische Anfälle nach Ischämie: Was bestimmt die Prognose?

09.07.2024 EAN-Congress 2024 Kongressbericht

Epileptische Anfälle, die im Gefolge eines ischämischen Insults auftreten, können weitere unprovozierte Anfälle nach sich ziehen und gehen mit einer erhöhten Mortalität einher. Die Prognose hängt von mehreren Faktoren ab. 

Restless-Legs-Syndrom: Peroneusstimulation als Therapie der Zukunft?

08.07.2024 EAN-Congress 2024 Kongressbericht

Die Möglichkeiten der Pharmakotherapie sind beim Restless-Legs-Syndrom begrenzt. Gefürchtet ist die Augmentation, insbesondere unter dopaminergen Wirkstoffen. Gehört die Zukunft deshalb der beidseitigen Stimulation der Peroneusnerven?